NasdaqCM - Nasdaq Real Time Price USD

Equillium, Inc. (EQ)

0.5992

-0.0008

(-0.13%)

As of 2:22:47 PM EST. Market Open.

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

LA JOLLA, Calif., November 13, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates.

Business Wire last month

EQ
-0.13%
Equillium to Present at the Stifel Healthcare Conference

LA JOLLA, Calif., November 13, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Stifel Healthcare Conference taking place in New York on November 18 & 19, 2024.

Business Wire last month

EQ
-0.13%
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

LA JOLLA, Calif., November 12, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented over the weekend at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024.

Business Wire last month

EQ
-0.13%
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

EQ
-0.13%
SPRO
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of 0% and 4.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

EQ
-0.13%
Equillium Maintains Rights to Itolizumab Following Ono Partnership

LA JOLLA, Calif., October 31, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium’s rights to itolizumab to expire. The decision was not related to data from any clinical program and there have been no obse

Business Wire last month

EQ
-0.13%
Alto Ingredients And 2 Other US Penny Stocks To Watch Closely

As major U.S. stock indexes experience slight declines amid a wave of earnings reports, investors are keeping a close eye on market movements and economic indicators. In this context, penny stocks—once considered speculative investments—remain relevant for those seeking opportunities in smaller or newer companies with solid financials. These stocks can offer potential growth at lower price points, especially when backed by strong balance sheets and fundamentals.

Simply Wall St. last month

EQ
-0.13%
GROV

GROVW
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

LA JOLLA, Calif., October 07, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference will take place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024.

Business Wire 2 months ago

EQ
-0.13%
Equillium collaborates with Vivtex for oral formulation of autoimmune therapy

The partnership will see the application of AI-enabled screening to address bioavailability issues with Equillium’s cytokine-targeting peptide.

Pharmaceutical Technology 3 months ago

EQ
-0.13%
GLDAF
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

LA JOLLA, Calif., September 10, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present and host investor meetings at the Stifel Virtual Inflammation & Immunology Summit taking place on September 17 & 18.

Business Wire 3 months ago

EQ
-0.13%
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., September 04, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on August 30, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 10,000 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committe

Business Wire 3 months ago

EQ
-0.13%
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

LA JOLLA, Calif., August 28, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present and host investor meetings at the Wells Fargo Healthcare Conference and H.C. Wainwright’s 26th Annual Global Investor Conference.

Business Wire 3 months ago

EQ
-0.13%
Equillium Second Quarter 2024 Earnings: Beats Expectations

Equillium ( NASDAQ:EQ ) Second Quarter 2024 Results Key Financial Results Revenue: US$13.9m (up 52% from 2Q 2023). Net...

Simply Wall St. 4 months ago

EQ
-0.13%
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates

Equillium (EQ) delivered earnings and revenue surprises of 106.67% and 69.98%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

EQ
-0.13%
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

LA JOLLA, Calif., August 08, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter 2024 and provided an update on corporate and clinical highlights.

Business Wire 4 months ago

EQ
-0.13%
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

LA JOLLA, Calif., August 06, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) based on its review of the interim results from the Phase 3 EQUATOR study evaluating itolizumab in subjects with acute graft-versus-host disease (aGVHD). The IDMC reviewed unblinded data on over 100 patie

Business Wire 4 months ago

EQ
-0.13%
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

LA JOLLA, Calif., July 18, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. The increase is primarily the result of receiving a tax credit of app

Business Wire 5 months ago

EQ
-0.13%
Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., July 02, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the JonesTrading Healthcare Seaside Summit.

Business Wire 5 months ago

EQ
-0.13%
Equillium to be included in the Russell Microcap® Index

LA JOLLA, Calif., June 12, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.

Business Wire 6 months ago

EQ
-0.13%
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

LA JOLLA, Calif., June 04, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA), an autoimmune disease driven by an immune cell attack of the hair follicles that

Business Wire 6 months ago

EQ
-0.13%

Performance Overview

Return	EQ	S&P 500
YTD	-16.78%	+25.00%
1-Year	-15.61%	+25.04%
3-Year	-86.10%	+29.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Equillium, Inc. (EQ)

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Alto Ingredients And 2 Other US Penny Stocks To Watch Closely

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium collaborates with Vivtex for oral formulation of autoimmune therapy

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Second Quarter 2024 Earnings: Beats Expectations

Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to Participate in Upcoming Investor Conferences

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Performance Overview